Search Results

• • 19 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects

  Authors:Andreas Pfutzner, Christian A Schneider, and Thomas ForstFrom:Expert Review of Cardiovascular Therapy (Vol. 4, Issue 4) Peer-Reviewed

  July 200611,633 words Report Author(s): Andreas Pfützner 1 , Christian A Schneider 2 , Thomas Forst 3 Keywords: cardiovascular disease; insulin resistance; pioglitazone; thiazolidinediones; Type 2 diabetes mellitus According to recent...

• Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial

  Authors:Juris J. Meier, Julio Rosenstock, Agnes Hincelin-Mery, Christine Roy-Duval, Astrid Delfolie, Hans-Veit Coester, et al.From:Diabetes Care (Vol. 38, Issue 7) Peer-Reviewed

  July 2015 Report

   Citation Only

• The Influence of Local Capsaicin Treatment on Small Nerve Fibre Function and Neurovascular Control in Symptomatic Diabetic Neuropathy

  Authors:THOMAS POHLMANN, THOMAS KUNT, KBROM GOITOM, ANDREAS PFUETZNER, MIRIAM LOEBIG, MARTIN ENGELBACH, et al.From:Diabetes (Vol. 49, Issue 5) Peer-Reviewed

  May 2000303 words Brief article Topical treatment with Capsaicin creme has been shown to be successful in the treatment of different symptomatic nerve disorders like diabetic neuropathy. Conflicting data exists on the effect of capsaicin on nerve...

• Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)

  Authors:Matthew C. Riddle, Thomas Forst, Ronnie Aronson, Leobardo Sauque-Reyna, Elisabeth Souhami, Louise Silvestre, et al.From:Diabetes Care (Vol. 36, Issue 9) Peer-Reviewed

  Sept. 20134,702 words Report 1480LOBJECTIVE--When oral therapy for type 2 diabetes is ineffective, adding basal insulin improves glycemic control. However, when glycated hemoglobin ([HbA.sub.1c]) remains elevated because of postprandial hyperglycemia,...

• Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes

  Authors:Thomas Forst, Andreas Pfutzner, Frank Flacke, Alan Krasner, Cloth Hohberg, Eda Tarakci, et al.From:Diabetes Care (Vol. 33, Issue 1) Peer-Reviewed

  Jan. 20103,893 words Article 1540LOBJECTIVE--Recent studies suggested an impact of prandial insulin delivery on postprandial regulation of tissue blood flow. This study compared the effect of VIAject with human regular insulin and insulin lispro on...

• Effect of insulin glulisine on microvascular blood flow and endothelial function in the postprandial state

  Authors:Clothilde Hohberg, Thomas Forst, Martin Larbig, Michael Safinowski, Stefan Diessel, Silvia Hehenwarter, et al.From:Diabetes Care (Vol. 31, Issue 5) Peer-Reviewed

  May 20083,357 words Clinical report 1540LOBJECTIVE--To investigate the effect of insulin glulisine on postprandial microvascular blood flow in type 2 diabetes. RESEARCH DESIGN AND METHODS--A total of 15 patients with type 2 diabetes received insulin...

• Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

  Authors:Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, et al.From:The Lancet (Vol. 394, Issue 10193) Peer-Reviewed

  July 13, 20193,935 words Article

   Abstract Only

• Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes

  Authors:Andreas Pfutzner, Thomas Kunt, Cloth Hohberg, Agnes Mondok, Sabine Pahler, Thomas Konrad, et al.From:Diabetes Care (Vol. 27, Issue 3) Peer-Reviewed

  Mar. 20043,558 words Article OBJECTIVE--In later stages of type 2 diabetes, proinsulin and proinsulin-like molecules are secreted in increasing amounts with insulin. A recently introduced chemiluminescence assay is able to detect the uncleaved...

• Incidence of Subclinical Sensory Trigeminal Nerve Fibre Involvement in Diabetes Mellitus

  Authors:THOMAS FORST, KBROM GOITOM, PETER URBAN, THOMAS KUNT, THOMAS POHLMANN, JUERGEN BEYER, et al.From:Diabetes (Vol. 49, Issue 5) Peer-Reviewed

  May 2000240 words Brief article Clinically apparent cranial nerve lesions associated with diabetes mellitus are relatively rare. Apart of this clinical observations, the frequency of subclinical cranial nerve fibre dysfunction in patients with...

• Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus

  Authors:Thomas Forst and Andreas PfutznerFrom:Expert Review of Endocrinology & Metabolism (Vol. 8, Issue 1) Peer-Reviewed

  Jan. 201311,682 words Article 1520LAuthor(s): Thomas Forst [*] 2 , Andreas Pfützner 1 Keywords : dipeptidyl peptidase-4 inhibitor; linagliptin; Type 2 diabetes mellitus A recent report of the International Diabetes Federation estimates that...

• Elevated Peripheral Visfatin Levels in Narcoleptic Patients

  Authors:Norbert Dahmen, Nina Manderscheid, Jana Helfrich, Petra B. Musholt, Thomas Forst, Andreas Pfutzner, et al.From:PLoS ONE (Vol. 3, Issue 8) Peer-Reviewed

  Aug. 20, 20083,792 words Article 1390LObjective Narcolepsy is a severe sleep disorder that is characterized by excessive daytime sleepiness, cataplexies and a tendency towards obesity. Recent discoveries indicate that the major pathophysiology is a loss...

• Proinsulin C-Peptide Restores Decreased Erythrocyte Deformability in Type 1 Diabetes Patients

  Authors:THOMAS KUNT, STEPHAN SCHNEIDER, THOMAS FORST, ANDREAS PFUETZNER, MARTIN ENGELBACH, MIRJAM LOEBIG, et al.From:Diabetes (Vol. 48, Issue 5) Peer-Reviewed

  May 1999257 words Abstract, Brief arti... Recent studies have demonstrated that proinsulin C-peptide reveals microvascular effects, probably by activating endothelial nitric oxide synthase. The aim of this study was to investigate the influence of proinsulin...

• Anti-diabetic treatment regulates pro-fibrotic TGF-[beta] serum levels in type 2 diabetics

  Authors:Stefan Pscherer, Thomas Freude, Thomas Forst, Andreas K Nussler, Karl F Braun, and Sabrina EhnertFrom:Diabetology & Metabolic Syndrome (Vol. 5, Issue 1) Peer-Reviewed

  Aug. 31, 20132,771 words Report 1490LBackground The single-center, open-label, four-arm, exploratory study investigates the relation of different anti-diabetics to serum levels of active TGF-[beta], a known pro-fibrotic stimulus, before and after a...

• Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: a 180-day, prospective, multicenter, pivotal trial

  Authors:Jort Kropff, Pratik Choudhary, Katharine Barnard, Sankalpa Neupane, Steve C. Bain, Christoph Kapitza, et al.From:Diabetes Care (Vol. 40, Issue 1) Peer-Reviewed

  Jan. 2017 Article

   Citation Only

• Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

  Authors:Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, et al.From:The Lancet (Vol. 394, Issue 10193) Peer-Reviewed

  July 13, 20193,949 words Article

   Abstract Only

• Fixed-dose combination of pioglitazone and glimepiride in the treatment of Type 2 diabetes mellitus

  Authors:Thomas Forst and Andreas PfutznerFrom:Expert Review of Endocrinology & Metabolism (Vol. 2, Issue 3) Peer-Reviewed

  May 20077,432 words Article 1380LAuthor(s): Thomas Forst [[dagger]] 1 , Andreas Pfützner 2 Keywords: Type 2 diabetes mellitus; glimepiride; pioglitazone; sulfonylurea; thiazolidinediones The incidence of Type 2 diabetes mellitus is...

• Development and validation of a new measure to evaluate psychological resistance to insulin treatment

  Authors:Frank Petrak, Elmar Stridde, Friedhelm Leverkus, Alexander A. Crispin, Thomas Forst, and Andreas PfutznerFrom:Diabetes Care (Vol. 30, Issue 9) Peer-Reviewed

  Sept. 20073,796 words Clinical report 1460LOBJECTIVE--To develop a psychometric questionnaire to measure psychological barriers to insulin treatment in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS--Scale development was based on principal...

• Proinsulin C-Peptide increases Plasma c-GMP Levels and the Endothelium-Dependent Microvascular Response in Type 1 Diabetic Patients

  Authors:THOMAS FORST, THOMAS KUNT, THOMAS POHLMANN, KBROM GOITOM, STEFAN SCHNEIDER, MIRIAM LOEBIG, et al.From:Diabetes (Vol. 48, Issue 5) Peer-Reviewed

  May 1999423 words Abstract Human proinsulin C-peptide has shown to influence microvascular blood flow in type I diabetic patients, which is thought to be mediated by an activation of endothelial NO-synthase and an increase in cyclic...

• Development and validation of a high-throughput screening method for two polymorphisms in the serotonin transporter gene

  Authors:Moritz Eidens, Alexander Weise, Stefan Prause, Norbert Dahmen, Annette Wunsch, Mathias Max Weber, et al.From:Molecular Diagnosis & Therapy (Vol. 13, Issue 1) Peer-Reviewed

  January-February 20092,450 words Report Background and Aim: The human serotonin (5-hydroxytryptamine) transporter, encoded by the SLC6A4 gene on chromosome 17q11.1-q12, is the cellular reuptake site for serotonin and a site of action for several drugs with...